Company intelligence / Profile preview

S.T.U.

Stuart, Florida, United States

Ownership: Private
Development stage: Other

Overview

Clinical stage company with ST-100 completing Phase 2 in dry eye disease, demonstrating corneal nerve repair, lacrimal function restoration, visual acuity improvement from day 2, symptom relief from day 14, and meeting Schirmer's Responder endpoint at day 28. ST-113 in preclinical for glaucoma neuroprotection.

Therapeutic areas: Ophthalmology
Modalities: Synthetic proteinCollagen mimetic peptide
Industry: Biotech

Partnerships

Glaukos CorporationAJU Pharm Co. Ltd.

Beyond the preview

Go deeper on S.T.U..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S.T.U..

Explore the full profile